Devyser Diagnostics

Devyser Diagnostics EBITDA per Employee

The EBITDA per Employee of Devyser Diagnostics (DVYSR.ST) as of Oct 23, 2026 is 110,416.67 SEK. In the previous year, EBITDA per Employee was -607,291.67 SEK — a change of -118.18% (higher).

EBITDA per Employee

110,416.67SEK

YoY

-118.18%

Last updated:

EBITDA per Employee of Devyser Diagnostics is 2025 110,416.67 SEK. EBITDA per Employee of Devyser Diagnostics was 2024 -607,291.67 SEK. It decreases by -118.18% higher compared to the previous year.

The Devyser Diagnostics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-36,562.50 SEK
Jan 1, 2019
90,083.33 SEK
Jan 1, 2020
-72,458.33 SEK
Jan 1, 2021
-224,614.58 SEK
Jan 1, 2022
-572,375.00 SEK
Jan 1, 2023
-588,541.67 SEK
Jan 1, 2024
-607,291.67 SEK
Jan 1, 2025
110,416.67 SEK
The Devyser Diagnostics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
110,416.67SEK-118.18%
-607,291.67SEK+3.19%
-588,541.67SEK+2.82%
-572,375.00SEK+154.83%
-224,614.58SEK+209.99%
-72,458.33SEK-180.43%
90,083.33SEK-346.38%
-36,562.50SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB develops and sells genetic testing kits for routine diagnostics, targeting hereditary diseases, oncology, and post-transplantation monitoring. The company offers products like Devyser Thrombophilia assay and Devyser Resolution XY, which analyze DNA for diagnosing genetic conditions and guiding cancer treatment. These kits are sold directly to end customers or through hired distributors across more than 45 countries, with nearly 30 products developed since inception. The firm generates revenue through direct sales and distributor partnerships, focusing on healthcare providers and laboratories that require genetic testing solutions. Its products are used in complex DNA analysis for diagnosing hereditary disorders and optimizing cancer therapies, serving a global market in over 45 countries without relying on third-party brands or external partnerships beyond its own product portfolio. Devyser Diagnostics AB's business model centers on selling its proprietary genetic testing kits, with no mention of additional services or third-party collaborations. The company's revenue streams are derived solely from product sales, targeting healthcare institutions that utilize DNA testing for diagnostic and therapeutic purposes in specialized medical fields. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

EBITDA per Employee of Devyser Diagnostics is 110,416.67 SEK in 2025.

EBITDA per Employee of Devyser Diagnostics changed from -607,291.67 SEK to 110,416.67 SEK, representing a -118.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Devyser Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics